Scrip    Clinica    Scrip Regulatory Affairs    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK Promote your vacancy here
AB Science jumps as masitinib outperforms in Phase II trial
03 February 2012
Shares in French biotech firm AB Science increase shot up by as much as 72% on 2 February on Phase II data showing its investigational targeted anticancer compound masitinib was more effective and better tolerated than the current standard of care, Sutent (sunitinib), in patients with Glivec-resistant GIST. Masitinib is already approved for veterinary use, as a treatment for canine mast cell tumour. AB Sciences expects to seek a partner when it comes to market the product for human uses. The ...
 
AB Science jumps as masitinib outperforms in Phase II trial
03 February 2012
Shares in French biotech firm AB Science increase shot up by as much as 72% on 2 February on Phase II data showing its investigational targeted anticancer compound masitinib was more effective and better tolerated than the current standard of care, Sutent (sunitinib), in patients with ...
No exception for Agennix as sepsis claims another hopeful victim - talactoferrin
03 February 2012
Shares of Agennix succumbed to their biggest percentage fall in more than two years in Frankfurt trading upon an announcement that it was halting the Phase II/III OASIS trial of its oral immunotherapy talactoferrin (recombinant human lactoferrin) for severe sepsis. The trial showed that ...
 
Merck fails to secure expanded indications for two cardiovascular products
27 January 2012
The US FDA has declined to approve a new indication for two Merck & Co products, Vytorin (ezetimibe/simvastatin) and Zetia (ezetimibe), because the study submitted to the agency did not assess the independent contributions of the individual drugs towards the efficacy result. The decision was in ...
Novartis's misfortunes with Gilenya could provide a boost for other MS drug makers
24 January 2012
The misfortunes suffered by Novartis with its multiple sclerosis (MS) drug, Gilenya (fingolimod), could provide an unexpected advantage to rival players in this market. Teva and Biogen Idec have already seen their share price boosted, while some analysts believe Novartis needs to take swift action ...
 
Commentary: Is Amgen exploiting poor European immigrants?
31 January 2012
Amgen, it appears, likes to exploit European immigrants as a shield against poor financial performance. Just one year ago, on 24 January 2011, in the same breath as it was revealing its 2010 full year financial results, Amgen announced a $1 billion deal to acquire cancer vaccine specialist, ...
Voluntary 'pause' in controversial H5N1 virus research lauded
24 January 2012
A month after the US government asked scientists to hold off publishing the details of their research describing a genetically-modified form of the H5N1 avian flu virus, which has been found to be highly transmissible in ferrets, over worries terrorists could usethe information for harmful ...
 
FDA rejection of Dapagliflozin creates uncertainty for other SGLT-2 inhibitors
20 January 2012
Dapagliflozin, the most advanced candidate in the novel SGLT-2 inhibitor antidiabetic class, was the subject of a complete response letter from the FDA, co-developers Bristol-Myers Squibb and AstraZeneca announced on 19 January 2012. The letter was not unexpected, given a negative 9-6 vote from an ...
Scotland says yes to BI/Lilly's Tradjenta and Lilly's Bydureon
17 January 2012
Scotland's health technology appraisal body, the Scottish Medicines Consortium (SMC) has said a partial yes to two anti-diabetics drugs, Boehringer Ingelheim/Lilly's DPP-4 inhibitor Tradjenta (linagliptin) and Lilly's GLP1-agonist Bydureon (prolonged-release exenatide). Meanwhile it has given ...
 
Fermenta readies for more sunshine; plans multi-forked growth for vitamin D3
03 February 2012
Fermenta Biotech, the only Indian manufacturer of vitamin D3, has doubled production capacity and expects to raise that further as the growing recognition and understanding of the nutritional and medical benefits of vitamin D3 expand global market opportunities. The company has charted out a ...
Infinity minus one: shares plummet as spiky saridegib fails in pancreatic cancer
30 January 2012
Infinity Pharmaceuticals has halted a Phase II trial of one of its key clinical programmes – for its experimental pancreatic cancer drug saridegib (also known as IPI-926), a Hedgehog pathway inhibitor, being studied in combination with gemcitabine. An interim analysis showed that there was better ...
 
StemCells gets FDA nod for dry AMD trial using neural stem cells
03 February 2012
Cell therapy specialist StemCells has received authorisation from the US FDA to start a Phase I/II trial of its purified human neural stem cells (HuCNS-SC) for dry age-related macular degeneration, or dry AMD. Dry AMD, the most common form of age-related macular degeneration, is the leading cause ...
XenoPort accuses GSK of contract breach, failing to maximise sales of Horizant
26 January 2012
XenoPort said it has delivered a breach of contract notice to GlaxoSmithKline, its commercial partner, alleging GSK has not met its obligation to maximise the US sales of their product, Horizant (gabapentin encarbil) extended-release tablets for restless legs syndrome (RLS), according to a 25 ...
 
No exception for Agennix as sepsis claims another hopeful victim - talactoferrin
03 February 2012
Shares of Agennix succumbed to their biggest percentage fall in more than two years in Frankfurt trading upon an announcement that it was halting the Phase II/III OASIS trial of its oral immunotherapy talactoferrin (recombinant human lactoferrin) for severe sepsis. The trial showed that ...
Impax licenses US Zomig rights from AstraZeneca
02 February 2012
Impax Pharmaceuticals - the branded products business unit of Impax Laboratories - has licensed from AstraZeneca the exclusive US rights to the migraine treatment, Zomig (zolmitriptan), in its tablet, orally disintegrating tablet, and nasal spray formulations. Under the agreement, Impax will pay ...
 
ViroPharma buys first dibs on budesonide formulation for emerging disease
28 December 2011
Rare disease-focused biopharma firm ViroPharma has signed an exclusive option deal to acquire Meritage Pharma , a privately owned firm developing an oral suspension of the anti-inflammatory budesonide to treat a recently classified chronic disease characterised by difficulty swallowing, food ...
Ironwood and CSO sued by Synergy over guanylate cyclase receptor agonists
16 December 2011
Ironwood Pharmaceuticals, a Cambridge, Massachusetts biotechnology firm, is facing a lawsuit seeking $500 million in damages by Synergy Pharmaceuticals, a New York-based firm. Both firms are developing drugs in the gastro-intestinal area. Synergy said in a statement that it filed a lawsuit in New ...
 
What do promising prostate cancer drug results mean for Dendreon?
02 February 2012
Three months ago, Medivation announced encouraging top-line results for the prostate cancer androgen receptor signalling inhibitor it is developing in conjunction with Astellas Pharma ( scripintelligence.com, 3 November 2011 ). On February 1 it released more details of the findings of its AFFIRM ...
Fermenta readies for more sunshine; plans multi-forked growth for vitamin D3
03 February 2012
Fermenta Biotech, the only Indian manufacturer of vitamin D3, has doubled production capacity and expects to raise that further as the growing recognition and understanding of the nutritional and medical benefits of vitamin D3 expand global market opportunities. The company has charted out a ...
 
The Alzheimer's development crisis: here's how we must change
23 January 2012
Christopher Bowe
Dimebon (latrepirdine) is dead. It didn’t come as much of a shock when Pfizer and Medivation ...

2012 Scrip 100: Successful trial outcomes – peering into the crystal ball
29 December 2011

With rising trial costs and shrinking budgets, pharma companies are working more diligently than ...

2012 Scrip 100: Get connected with mHealth
28 December 2011

Pharmaceuticals and telecommunications have much in common. They are mature, highly-regulated ...

2012 Scrip 100: The French fallout
22 December 2011

The Mediator affair was without doubt the most disruptive event in the European regulatory arena ...

Biopharma investors set plans for expedited ROI by developing products, not companies
29 November 2011
If the biotechnology industry initially embraced a credo of "The Little Engine that Could" – the ...

Dx by dt: diagnostic intent over time
03 February 2012
Mike Ward
If Roche acquires Illumina, as it seems fairly intent on doing despite repeated messages of ...

DKSH highlights one-stop benefits as it builds Asia market expansion services
19 January 2012
Ian Haydock
After a decade as an officer in the British Royal Marines, Charles Toomey was well prepared for ...

© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
Scrip Regulatory Affairs
Scrip Clinical Research
Animal Pharm